Skip to main content
Steven Treon, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

StevenPTreonMD

Oncology Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Dr. Treon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Treon's full profile

Already have an account?

Summary

  • Dr. Steven Treon is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, and North Shore Medical Center. He received his medical degree from Boston University School of Medicine and has been in practice 24 years. He specializes in hematologic oncology and is experienced in hematologic oncology and waldenstrom macroglobulinemia.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1992 - 1995
  • Boston University School of Medicine
    Boston University School of MedicineClass of 1993

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1994 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Bortezomib Overcomes the Negative Impact of CXCR4 Mutations on Survival of Waldenstrom's Macroglobulinemia Patients  
    Kaitlen Reyes, Steven P Treon, Irene M Ghobrial, Blood
  • TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinaemia  
    Toni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia  
    Jeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine

Abstracts/Posters

  • CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors
    Steven P Treon, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
  • A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 M...
    Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with Ibrutinib
    Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MY... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • FDA Greenlights BeiGene’s Brukinsa for Waldenstrom’s Macroglobulinemia
    FDA Greenlights BeiGene’s Brukinsa for Waldenstrom’s MacroglobulinemiaSeptember 2nd, 2021
  • U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
    U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s MacroglobulinemiaSeptember 1st, 2021
  • BTK Blockers Make Headway in Multiple Sclerosis
    BTK Blockers Make Headway in Multiple SclerosisJanuary 11th, 2021
  • Join now to see all

Grant Support

  • Novel Serotherapy Strategies--Plasma Cell MalignanciesNational Cancer Institute2000–2004

Professional Memberships

Hospital Affiliations